AVCT.F Stock Overview Develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. More details
Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Avacta Group Plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Avacta Group Historical stock prices Current Share Price UK£0.62 52 Week High UK£1.33 52 Week Low UK£0.48 Beta 1.19 1 Month Change -10.09% 3 Month Change -4.48% 1 Year Change n/a 3 Year Change -35.75% 5 Year Change n/a Change since IPO -56.90%
Recent News & Updates
Avacta Therapeutics Announces Positive New Data from the AVA6000 Phase 1 Trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers Jan 16
Avacta Appoints Brian Hahn Chief Financial Officer Jan 14
Avacta Appoints Brian Hahn Chief Financial Officer Jan 13
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona Oct 24
Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform Oct 17
Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024 Oct 15 See more updates
Avacta Therapeutics Announces Positive New Data from the AVA6000 Phase 1 Trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers Jan 16
Avacta Appoints Brian Hahn Chief Financial Officer Jan 14
Avacta Appoints Brian Hahn Chief Financial Officer Jan 13
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona Oct 24
Avacta Group plc Expands Its Pipeline with Two Novel Assets Developed Using Its Pre|CISION Platform Oct 17
Avacta Group plc Appoints Michelle Morrow as Chief Scientific Officer, Effective November 4, 2024 Oct 15
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs At 2024 Eortc-Nci-Aacr Symposium Oct 10
Avacta Group plc Reports Updated Phase 1 Data of Ava6000 At the European Society for Medical Oncology Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors Sep 16
Avacta Group Plc to Report First Half, 2024 Results on Sep 30, 2024 Sep 12
Avacta Group plc Announces Board Changes Jun 26
Avacta Group plc Announces Board Changes Jun 21
Avacta Group Plc, Annual General Meeting, Jun 26, 2024 Jun 02
Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial May 25
Avacta Group plc Announces Chief Executive Officer Changes May 01
Avacta Group plc Announces Chief Executive Officer Changes Apr 30
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting Apr 10
Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress Mar 21
Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million. Mar 05 Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million. Mar 01
Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer Jan 19
Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division Dec 19
Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study Dec 13
Avacta Group Plc Announces Management Changes Sep 21
Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation Sep 19
Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023 Sep 06
Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study Jun 22
Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director Jun 20
Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620). Jun 06
Avacta Group Plc, Annual General Meeting, Jun 28, 2023 Jun 03
Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million. Jun 01
Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study Jan 17
Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million. Oct 19
Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022 Sep 28
Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort Sep 01 Avacta Group Plc announced that it has received funding Jul 22
Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin Jun 29
Avacta Group Plc, Annual General Meeting, Jun 23, 2022 May 31 Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London May 12
Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022 Mar 31
Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022 Mar 30
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin Feb 04
Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development Jan 19
Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant Jan 12
Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU Dec 23
Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant Dec 16
Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000 Nov 29
Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership Oct 02
Avacta Group plc Provides Update on AffiDX Lateral Flow Test Aug 06
Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU Jun 12
MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test Jun 08
Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions Jun 02 Avacta Signs Diagnostic Licensing Deal with Biokit
Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus Mar 09
Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA Feb 18
Avacta Group plc Announces Results of Initial Evaluation of Sars-Cov-2 Lateral Flow Antigen Test with Clinical Samples Feb 16
Avacta Group plc Enters into Commercial Partnership with Mologic Ltd Feb 09 Avacta Announces Collaboration Agreement with Bruker
Avacta Group plc Announces License Agreement with Point Biopharma Inc Jan 08
Avacta Submits Clinical Trial Application for Ava6000 Pro-Doxorubixin Dec 25
Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology Dec 23
Avacta Group plc Announces Significant Progress in Development of a Highly Scalable Manufacturing Process for Lateral Flow SARS-CoV-2 Antigen Test Nov 24
Avacta Group Plc Launches SARS-CoV-2 BAMS Research Test Oct 01 Shareholder Returns AVCT.F US Biotechs US Market 7D 2.2% -4.2% 0.2% 1Y n/a -3.0% 23.1%
See full shareholder returns
Return vs Industry: Insufficient data to determine how AVCT.F performed against the US Biotechs industry .
Return vs Market: Insufficient data to determine how AVCT.F performed against the US Market .
Price Volatility Is AVCT.F's price volatile compared to industry and market? AVCT.F volatility AVCT.F Average Weekly Movement n/a Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: AVCT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AVCT.F's volatility change over the past year.
About the Company Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets.
Show more Avacta Group Plc Fundamentals Summary How do Avacta Group's earnings and revenue compare to its market cap? AVCT.F fundamental statistics Market cap US$208.56m Earnings (TTM ) -US$32.22m Revenue (TTM ) US$28.15m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AVCT.F income statement (TTM ) Revenue UK£22.62m Cost of Revenue UK£13.10m Gross Profit UK£9.52m Other Expenses UK£35.40m Earnings -UK£25.89m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.071 Gross Margin 42.08% Net Profit Margin -114.45% Debt/Equity Ratio 49.8%
How did AVCT.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 23:05 End of Day Share Price 2025/02/06 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Avacta Group Plc is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Vadim Alexandre Khalil Daniel Stewart & Company Lorenza Castellon Equity Development Limited Paul Cuddon Numis Securities Ltd.
Show 4 more analysts 
